Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Tong Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9987-8256; OpenAlex author ID A5100359044. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2020: 4 papers · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 9

  1. Pancreatic cancer cell-derived migrasomes promote cancer progression by fostering an immunosuppressive tumor microenvironment. Co-author DOI 10.1016/j.canlet.2024.217289↗
  2. Up-Regulated MISP Is Associated With Poor Prognosis and Immune Infiltration in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2022.827051↗
  3. Dopamine improves chemotherapeutic efficacy for pancreatic cancer by regulating macrophage-derived inflammations. Co-author DOI 10.1007/s00262-020-02816-0↗
  4. The promoting effects of hsa_circ_0050102 in pancreatic cancer and the molecular mechanism by targeting miR-1182/NPSR1. Co-author DOI 10.1093/carcin/bgaa130↗
  5. Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy. Co-author DOI 10.1186/s12935-021-01824-z↗
  6. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Co-author DOI 10.1007/s00262-020-02542-7↗
  7. Up-regulation of CDHR5 expression promotes malignant phenotype of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jcmm.15856↗
  8. Identification of prognosis-related genes and construction of multi-regulatory networks in pancreatic cancer microenvironment by bioinformatics analysis. Co-author DOI 10.1186/s12935-020-01426-1↗
  9. CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration. Co-author DOI 10.7150/jca.40517↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qiaofei Liu · 5 shared papers, 2020–2024 · strength 0.71
  2. Junyi Gao · 5 shared papers, 2020–2024 · strength 0.65
  3. Ming Cui · 5 shared papers, 2020–2024 · strength 0.63
  4. Ronghua Zhang · 5 shared papers, 2020–2024 · strength 0.63
  5. Quan Liao · 5 shared papers, 2020–2021 · strength 0.58
  6. Quan Liao · 3 shared papers, 2020–2024 · strength 0.47
  7. Xiang Zhang · 4 shared papers, 2020–2021 · strength 0.46
  8. Jingkai Liu · 4 shared papers, 2020–2021 · strength 0.46
  9. Yalu Zhang · 3 shared papers, 2021–2024 · strength 0.44
  10. Mengyi Wang · 3 shared papers, 2020–2021 · strength 0.38
  11. Yupei Zhao · 3 shared papers, 2020 · strength 0.34
  12. Sen Yang · 2 shared papers, 2021–2024 · strength 0.29
  13. Junya Peng · 2 shared papers, 2020–2024 · strength 0.28
  14. Lei You · 2 shared papers, 2020–2021 · strength 0.27
  15. Jorg H. Kleeff · 2 shared papers, 2020–2024 · strength 0.26
  16. Qiaofei Liu · 2 shared papers, 2020–2021 · strength 0.20
  17. Huanwen Wu · 2 shared papers, 2020–2021 · strength 0.20
  18. Xinyang Huang · 1 shared paper, 2022 · strength 0.16
  19. Liangchao Zhao · 1 shared paper, 2022 · strength 0.16
  20. Lifu Wang · 1 shared paper, 2022 · strength 0.16
  21. Hui Xu · 1 shared paper, 2022 · strength 0.16
  22. Zhuoxin Wang · 1 shared paper, 2022 · strength 0.16
  23. Yixun Jin · 1 shared paper, 2022 · strength 0.16
  24. Qi Wang · 1 shared paper, 2022 · strength 0.16
  25. Surong Hua · 1 shared paper, 2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.